Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/31730
Title: | Treatment of Idiopathic Pulmonary Fibrosis with Etanercept An Exploratory, Placebo-controlled Trial | Authors: | Raghu, G Brown, KK Costabel, U Cottin, V du Bois, RM Lasky, JA THOMEER, Michiel Utz, JP Khandker, RK McDermott, L Fatenejad, S |
Issue Date: | 2008 | Publisher: | AMER THORACIC SOC | Source: | American journal of respiratory and critical care medicine, 178 (9) , p. 948 -955 | Abstract: | Rationale: An efficacious medical therapy for idiopathic pulmonary fibrosis (IPF) remains elusive.Objectives: To explore the efficacy and safety of etanercept in the treatment of IPF.Methods: This was a randomized, prospective, double-blind, placebo-controlled, multicenter exploratory trial in subjects with clinically progressive IPF. Primary endpoints included changes in the percentage of predicted FVC and lung cliff using capacity for carbon monoxide corrected for hemoglobin (D-LCOHB) and change in the alveolar to arterial oxygen pressure difference P(A-a)(O2) at rest from baseline over 48 weeks.Measurements and Main Results: Eighty-eight subjects received subcutaneous etanercept (25 mg) or placebo twice weekly as their sole treatment for IPF. No differences in baseline demographics and disease status were detected between treatment groups; the mean time from first diagnosis was 13.6 months and mean FVC was 63.9% of predicted. At 48 weeks, no significant differences in efficacy end points were observed between the groups. A nonsignificant reduction in disease progression was seen in several physiologic, functional, and quality-of-life endpoints among subjects receiving etanercept. There was no difference in adverse events between treatment groups.Conclusions: In this exploratory study in patients with clinically progressive IPF, etanercept was well tolerated. Although there were no differences in the predefined endpoints, a decreased rate of disease progression was observed on several measures. Further evaluation of TNF antagonists in the treatment of IPF may be warranted. | Keywords: | Idiopathic pulmonary fibrosis;etanercept;tumor necrosis factor antagonist;quality of life;placebo-controlled | Document URI: | http://hdl.handle.net/1942/31730 | ISSN: | 1073-449X | e-ISSN: | 1535-4970 | DOI: | 10.1164/rccm.200709-1446OC | ISI #: | WOS:000260611600012 | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
etanerceptIPF.pdf Restricted Access | Published version | 171.9 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
242
checked on Sep 7, 2020
WEB OF SCIENCETM
Citations
290
checked on Oct 14, 2024
Page view(s)
24
checked on Sep 7, 2022
Download(s)
4
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.